FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant production of fusion proteins based on Growth/Differentiation Factor 15 (GDF15) and can be used in medicine to reduce body weight, control diet and prevent or treat a metabolic disease. A fusion polypeptide was constructed comprising GDF15 or a functional deleted variant thereof, to the N-terminus of which one strand of the human IgG4 Fc region was attached via a flexible peptide linker.
EFFECT: invention makes it possible to obtain a fusion polypeptide with an extended period of existence of GDF15 in vivo.
19 cl, 11 dwg, 13 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LONG-ACTING FUSION PROTEIN GDF15 AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2836280C1 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| FUSION POLYPEPTIDE CONTAINING GDF15 AND POLYPEPTIDE REGION CAPABLE OF O-GLYCOSYLATION | 2020 |
|
RU2812049C1 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| NEW MODIFIED IMMUNOGLOBULIN Fc-FRAGMENT FUNCTION PROTEIN AND ITS USE | 2020 |
|
RU2800919C2 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
